FARON PHARMACEUTICALS OY
Clinical-stage biopharmaceutical company developing immunotherapies for cancer.
FARN | IL
Overview
Corporate Details
- ISIN(s):
- FI4000153309
- LEI:
- 7437009H31TO1DC0EB42
- Country:
- Finland
- Address:
- Joukahaisenkatu 6, FI-20520 TURKU
- Website:
- https://faron.com/
- Sector:
- Manufacturing
Description
Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-04-25 18:09 |
Holding(s) in Company
|
English | 53.8 KB | ||
| 2019-04-12 15:20 |
Holding(s) in Company
|
English | 54.0 KB | ||
| 2019-04-11 09:00 |
First expansion cohort for MATINS trial part 2
|
English | 26.0 KB | ||
| 2019-04-10 13:41 |
Holding(s) in Company
|
English | 54.7 KB | ||
| 2019-04-05 09:00 |
Notice of Results
|
English | 15.8 KB | ||
| 2019-04-02 11:23 |
Holdings in Company
|
English | 68.8 KB | ||
| 2019-03-28 13:54 |
Results of the Placing and Subscription
|
English | 60.1 KB | ||
| 2019-03-26 16:31 |
Result of Placing and Issue Price
|
English | 23.1 KB | ||
| 2019-03-26 08:00 |
Proposed Placing to raise approximately EUR 3m
|
English | 49.0 KB | ||
| 2019-02-21 08:00 |
MATINS study update
|
English | 25.3 KB | ||
| 2019-02-13 09:57 |
New data published by Clinical Cancer Research
|
English | 6.0 KB | ||
| 2018-12-19 08:00 |
Traumakine update - YODA results
|
English | 19.2 KB | ||
| 2018-12-14 12:20 |
First patient dosed in phase I/II MATINS study
|
English | 21.9 KB | ||
| 2018-12-11 17:26 |
Holding(s) in Company
|
English | 54.1 KB | ||
| 2018-12-05 08:00 |
Patient subgroup identified from INTEREST trial
|
English | 19.0 KB |
Automate Your Workflow. Get a real-time feed of all FARON PHARMACEUTICALS OY filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for FARON PHARMACEUTICALS OY
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for FARON PHARMACEUTICALS OY via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
